+ +

•  

   

     Western blot analysis of MBD3 expression in 293T cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

The MBD3 (methyl-CpG-binding domain protein 3) antibody is a crucial tool for studying epigenetic regulation and chromatin remodeling. MBD3 is a member of the methyl-CpG-binding domain protein family, which plays a role in gene silencing by recognizing methylated DNA. Unlike other MBD proteins (e.g., MBD1-4), MBD3 lacks strong methyl-binding activity but is an essential component of the NuRD (nucleosome remodeling and deacetylase) complex, linking DNA methylation to histone modification and chromatin structure modulation. The NuRD complex regulates gene expression through ATP-dependent chromatin remodeling and histone deacetylase (HDAC) activity, influencing processes like cellular differentiation, embryonic development, and tumor suppression.

MBD3 antibodies are widely used in research to investigate DNA methylation-dependent gene regulation, stem cell pluripotency, and cancer biology. They enable the detection and localization of MBD3 in techniques such as Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP). These antibodies help elucidate MBD3's role in maintaining embryonic stem cell identity, where it stabilizes the NuRD complex to suppress differentiation. Dysregulation of MBD3 is associated with developmental disorders and malignancies, making it a potential biomarker or therapeutic target. Validating antibody specificity is critical, as cross-reactivity with other MBD family members (e.g., MBD2) could confound results. Researchers often use MBD3 antibodies in conjunction with methylation analysis to dissect epigenetic mechanisms in health and disease.